Status:
UNKNOWN
Epilepsy in Alzheimer's Disease: Effect on Disease Progression
Lead Sponsor:
Universitair Ziekenhuis Brussel
Conditions:
Mild Cognitive Impairment
Alzheimer Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a long-term, prospective, interventional study to investigate the role and prevalence of subclinical epileptiform activity in the hippocampus in patients with mild cognitive impairment (MCI) d...
Detailed Description
Epilepsy is a known comorbidity of Alzheimer's disease. In the past, it was considered to be a late complication of AD. Recent literature suggest seizures to be prevalent much earlier in the time cour...
Eligibility Criteria
Inclusion
- Patients
- Cognitive concern reflecting a change in cognition reported by patient or informant or clinician
- Objective evidence of impairment in one or more cognitive domains, typically including memory.
- Preservation of independence in functional abilities
- Not demented
Exclusion
- Age \< 18 years old
- Pregnancy
- Expected death due to illness within 2 years
- Pacemaker or other ferromagnetic material that is not MRI compatible
- Other neurodegenerative or cerebrovascular disease
- Pattern compatible with Normal Pressure Hydrocephalus (NPH) (clinically, imaging)
- Epilepsy
- Multiple sclerosis or other demyelinating disease
- Depression, psychosis or other mental disease
- Use of anti-epileptic drugs
- Alcohol or substance abuse
- Korsakoff syndrome
- Symptomatic liver disease
- Uncontrolled thyroid disorders
- Untreated HIV or syphilis
- Clinically significant vitamin B12 deficiency
- Severe systemic medical illness (eg end-stage cardiac disease, …)
- Healthy volunteers Inclusion criteria Age- and gender matched healthy controls
- Exclusion criteria
- Age \< 18 years old
- Pregnancy
- Pacemaker or other ferromagnetic material that is not MRI compatible
- Mild cognitive impairment or dementia of any cause
- Epilepsy
- Multiple sclerosis or other demyelinating disease
- Depression, psychosis or other mental disease
- Use of anti-epileptic drugs
- Alcohol or substance abuse
- Symptomatic liver disease
- Uncontrolled thyroid disorders
- Untreated HIV or syphilis
- Clinically significant vitamin B12 deficiency
- Severe systemic medical illness (eg end-stage cardiac disease, …)
Key Trial Info
Start Date :
February 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04131491
Start Date
February 12 2020
End Date
September 30 2023
Last Update
May 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Brussel
Brussels, Jette, Belgium, 1090